MELISSA DEER: Open Payments
NPI 1043415888 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,643 in 76 payments from 10 companies in 2025. Trend: 2023 $75 · 2024 $259 · 2025 $1,643
Food & beverage: $1,638Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $336 |
| Tris Pharma Inc | 3 | $214 |
| Alkermes, Inc. | 15 | $211 |
| Vanda Pharmaceuticals Inc. | 8 | $206 |
| Otsuka America Pharmaceutical, Inc. | 9 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $147 |
| E.R. Squibb & Sons, L.L.C. | 5 | $108 |
| Janssen Pharmaceuticals, Inc | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $95 |
| ABBVIE INC. | 3 | $57 |
Products named: INGREZZA, FANAPT, Dyanavel XR, ARISTADA, CAPLYTA, COBENFY, INVEGA SUSTENNA, REXULTI.
Industry payments across CA — which companies pay providers there.
